Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of lisocabtagene maraleucel in aggressive B-cell non-Hodgkin lymphoma
NL-OMON52985Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Nov 2018
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of lisocabtagene maraleucel in mature B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), large-cell lymphoma and 2 more (6 cohorts), sponsored by Celgene Corporation. Primary endpoints: Overall response rate in NHL cohorts, Overall response rate in primary CNS lymphoma cohort and 1 more. Started Nov 2018; status: completed.
02
Drugs
lisocabtagene maraleucel
03
Conditions
mature B-cell lymphomadiffuse large B-cell lymphoma (DLBCL)large-cell lymphomafollicular lymphoma (FL)primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NL-OMON52985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52985.